Summary

The global hematologic malignancies testing market is anticipated to observe impressive growth during the forecast period 2023-2027. The major factors, including growing occurrences of blood cancer and extensive development in technology, are fueling the growth of the market. Hematologic malignancies are cancers that affect the blood, bone marrow, and lymph nodes. Leukemia, lymphoma, and myeloma are the common types of blood cancer. Hematologic malignancies testing is a medical testing method that helps to diagnose blood cancer. The other factors supporting the market’s growth are a rise in R&D activities, increasing favorable government funding, rising emphasis on personalized medicine, increasing awareness among patients and healthcare professionals, rise in aging population base, growing adoption of inorganic growth strategies, an increasing number of product launches, and immense potential for emerging submarkets.
Increasing Occurrence of Blood-Related Disorders
The growing incidences of blood-related disorders, such as leukemia, lymphoma, and myeloma, are bolstering the growth of the market globally. According to the American Cancer Society, in the United States, around every 3 minutes, a person is diagnosed with leukemia, lymphoma, and myeloma. Owing to the rise in the number of patients who have hematologic cancer, the surge in the need for early detection and treatment of blood cancers is augmenting the growth of the market. Blood cancers are the fifth most common malignancy across the world and the second primary reason for cancer death. For instance, more than 300,000 people are diagnosed yearly with leukemia and 400,000 with lymphoma across the globe.
Technological Advancements and Rise in R&D Activities
The evolution of new technologies in the healthcare sector is surging the growth of the market. The increasing adoption of new innovative technologies, such as digital PCR, next-generation sequencing, cytogenetics, and others, is strengthening the growth of the market. The developments are helping to minimize the cost and time of treatment and improve the quality of human life. Moreover, the rise in R&D activities is propelling the growth of the market.
Increasing Adoption of Inorganic Growth Strategies
Growing inorganic growth strategies such as mergers, acquisitions, collaborations, partnerships, and an increasing number of product launches by market players are bolstering the growth of the market. For instance, in 2021, Natera, Inc., and Personalis, Inc. partnered in personalized oncology by coupling Personalis’ NeXT tumor profiling and diagnostic products with Natera’s personalized ctDNA platform Signatera for treatment monitoring and molecular residual disease assessment. Similarly, in 2018, Abbott launched an h-series incorporating a hematology system and has brought numerous changes in the clinical laboratories since then.
Market Segmentation
The global hematologic malignancies testing market is segmented into component, technique, therapeutic indication, end user, and company. Based on components, the market is divided into kits and services. Based on kits, the market is further divided into gene panels, molecular clonality testing, translocation testing, mutation testing, and others. Based on technique, the market is divided into next-generation sequencing (NGS), polymerase chain reaction (PCR), fluorescence in-situ hybridization (FISH), immunohistochemistry (IHC), and others. Based on therapeutic indication, the market is divided into leukemia, lymphoma, multiple myeloma, myeloproliferative neoplasms, and others. Based on end-user, the market is divided into hospitals & clinics, diagnostic laboratories, academic & research institutions, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rising incidences of blood cancers in the country.
Market Players
Abbott Laboratories, Inc., Asuragen Inc., Bio-Rad Laboratories, Inc., Adaptive Biotechnologies Corporation, F.Hoffmann-La-Roche AG, Illumina, Inc., ICON plc., Invitae Corporation, Laboratory Corporation of America Holdings, and Invivoscribe, Inc. are some of the leading companies operating in the market.
Report Scope:
In this report, global hematologic malignancies testing market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Hematologic Malignancies Testing Market, By Component:
o Kits
 Gene Panels
 Molecular Clonality Testing
 Translocation Testing
 Mutation Testing
 Others
o Services
• Hematologic Malignancies Testing Market, By Component:
o Next-Generation Sequencing (NGS)
o Polymerase Chain Reaction (PCR)
o Fluorescence In-Situ Hybridization (FISH)
o Immunohistochemistry (IHC)
o Others
• Hematologic Malignancies Testing Market, By Therapeutic Indication:
o Leukemia
o Lymphoma
o Multiple Myeloma
o Myeloproliferative Neoplasms
o Others
• Hematologic Malignancies Testing Market, By End User:
o Hospitals & Clinics
o Diagnostic Laboratories
o Academic & Research Institutions
o Others
• Hematologic Malignancies Testing Market, By Region:
o North America
 United States
 Canada
 Mexico
o Asia-Pacific
 China
 India
 Japan
 Australia
 South Korea
o Europe & CIS
 Germany
 France
 United Kingdom
 Spain
 Italy
o South America
 Brazil
 Argentina
 Colombia
o Middle East & Africa
 South Africa
 Saudi Arabia
 UAE
 Egypt
 Turkey
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in Global Hematologic Malignancies Testing Market
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
2. Research Methodology
3. Executive Summary
4. Impact of COVID-19 on Global Hematologic Malignancies Testing Market
5. Voice of Customer
6. Clinical Trial Analysis
7. Global Hematologic Malignancies Testing Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Component (Kits v/s Services)
7.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing, Translocation Testing, Mutation Testing, Others)
7.2.2. By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
7.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others)
7.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
7.2.5. By Company (2021)
7.2.6. By Region
7.3. Market Map
8. North America Hematologic Malignancies Testing Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Component (Kits v/s Services)
8.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing, Translocation Testing, Mutation Testing, Others)
8.2.2. By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
8.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others)
8.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
8.2.5. By Country
8.3. North America: Country Analysis
8.3.1. United States Hematologic Malignancies Testing Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Component
8.3.1.2.2. By Technique
8.3.1.2.3. By Therapeutic Indication
8.3.1.2.4. By End User
8.3.2. Canada Hematologic Malignancies Testing Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Component
8.3.2.2.2. By Technique
8.3.2.2.3. By Therapeutic Indication
8.3.2.2.4. By End User
8.3.3. Mexico Hematologic Malignancies Testing Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Component
8.3.3.2.2. By Technique
8.3.3.2.3. By Therapeutic Indication
8.3.3.2.4. By End User
9. Europe Hematologic Malignancies Testing Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Component (Kits v/s Services)
9.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing, Translocation Testing, Mutation Testing, Others)
9.2.2. By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
9.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others)
9.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
9.2.5. By Country
9.3. Europe: Country Analysis
9.3.1. France Hematologic Malignancies Testing Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Component
9.3.1.2.2. By Technique
9.3.1.2.3. By Therapeutic Indication
9.3.1.2.4. By End User
9.3.2. Germany Hematologic Malignancies Testing Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Component
9.3.2.2.2. By Technique
9.3.2.2.3. By Therapeutic Indication
9.3.2.2.4. By End User
9.3.3. United Kingdom Hematologic Malignancies Testing Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Component
9.3.3.2.2. By Technique
9.3.3.2.3. By Therapeutic Indication
9.3.3.2.4. By End User
9.3.4. Italy Hematologic Malignancies Testing Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Component
9.3.4.2.2. By Technique
9.3.4.2.3. By Therapeutic Indication
9.3.4.2.4. By End User
9.3.5. Spain Hematologic Malignancies Testing Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Component
9.3.5.2.2. By Technique
9.3.5.2.3. By Therapeutic Indication
9.3.5.2.4. By End User
10. Asia-Pacific Hematologic Malignancies Testing Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Component (Kits v/s Services)
10.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing, Translocation Testing, Mutation Testing, Others)
10.2.2. By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
10.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others)
10.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
10.2.5. By Country
10.3. Asia-Pacific: Country Analysis
10.3.1. China Hematologic Malignancies Testing Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Component
10.3.1.2.2. By Technique
10.3.1.2.3. By Therapeutic Indication
10.3.1.2.4. By End User
10.3.2. India Hematologic Malignancies Testing Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Component
10.3.2.2.2. By Technique
10.3.2.2.3. By Therapeutic Indication
10.3.2.2.4. By End User
10.3.3. Japan Hematologic Malignancies Testing Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Component
10.3.3.2.2. By Technique
10.3.3.2.3. By Therapeutic Indication
10.3.3.2.4. By End User
10.3.4. South Korea Hematologic Malignancies Testing Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Component
10.3.4.2.2. By Technique
10.3.4.2.3. By Therapeutic Indication
10.3.4.2.4. By End User
10.3.5. Australia Hematologic Malignancies Testing Market Outlook
10.3.5.1. Market Size & Forecast
10.3.5.1.1. By Value
10.3.5.2. Market Share & Forecast
10.3.5.2.1. By Component
10.3.5.2.2. By Technique
10.3.5.2.3. By Therapeutic Indication
10.3.5.2.4. By End User
11. South America Hematologic Malignancies Testing Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Component (Kits v/s Services)
11.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing, Translocation Testing, Mutation Testing, Others)
11.2.2. By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
11.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others)
11.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
11.2.5. By Country
11.3. South America: Country Analysis
11.3.1. Brazil Hematologic Malignancies Testing Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Component
11.3.1.2.2. By Technique
11.3.1.2.3. By Therapeutic Indication
11.3.1.2.4. By End User
11.3.2. Argentina Hematologic Malignancies Testing Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Component
11.3.2.2.2. By Technique
11.3.2.2.3. By Therapeutic Indication
11.3.2.2.4. By End User
11.3.3. Colombia Hematologic Malignancies Testing Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Component
11.3.3.2.2. By Technique
11.3.3.2.3. By Therapeutic Indication
11.3.3.2.4. By End User
12. Middle East and Africa Hematologic Malignancies Testing Market Outlook
12.1. Market Size & Forecast
12.1.1. By Value
12.2. Market Share & Forecast
12.2.1. By Component (Kits v/s Services)
12.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing, Translocation Testing, Mutation Testing, Others)
12.2.2. By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
12.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others)
12.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
12.2.5. By Country
12.3. MEA: Country Analysis
12.3.1. South Africa Hematologic Malignancies Testing Market Outlook
12.3.1.1. Market Size & Forecast
12.3.1.1.1. By Value
12.3.1.2. Market Share & Forecast
12.3.1.2.1. By Component
12.3.1.2.2. By Technique
12.3.1.2.3. By Therapeutic Indication
12.3.1.2.4. By End User
12.3.2. Saudi Arabia Hematologic Malignancies Testing Market Outlook
12.3.2.1. Market Size & Forecast
12.3.2.1.1. By Value
12.3.2.2. Market Share & Forecast
12.3.2.2.1. By Component
12.3.2.2.2. By Technique
12.3.2.2.3. By Therapeutic Indication
12.3.2.2.4. By End User
12.3.3. UAE Hematologic Malignancies Testing Market Outlook
12.3.3.1. Market Size & Forecast
12.3.3.1.1. By Value
12.3.3.2. Market Share & Forecast
12.3.3.2.1. By Component
12.3.3.2.2. By Technique
12.3.3.2.3. By Therapeutic Indication
12.3.3.2.4. By End User
12.3.4. Turkey Hematologic Malignancies Testing Market Outlook
12.3.4.1. Market Size & Forecast
12.3.4.1.1. By Value
12.3.4.2. Market Share & Forecast
12.3.4.2.1. By Component
12.3.4.2.2. By Technique
12.3.4.2.3. By Therapeutic Indication
12.3.4.2.4. By End User
12.3.5. Egypt Hematologic Malignancies Testing Market Outlook
12.3.5.1. Market Size & Forecast
12.3.5.1.1. By Value
12.3.5.2. Market Share & Forecast
12.3.5.2.1. By Component
12.3.5.2.2. By Technique
12.3.5.2.3. By Therapeutic Indication
12.3.5.2.4. By End User
13. Market Dynamics
13.1. Drivers
13.2. Challenges
14. Market Trends & Developments
15. Competitive Landscape
15.1. Abbott Laboratories, Inc.
15.2. Asuragen Inc.
15.3. Bio-Rad Laboratories, Inc.
15.4. Adaptive Biotechnologies Corporation
15.5. F.Hoffmann-La-Roche AG
15.6. Illumina, Inc.
15.7. ICON plc.
15.8. Invitae Corporation
15.9. Laboratory Corporation of America Holdings
15.10. Invivoscribe, Inc.
16. Strategic Recommendations